BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tang F, Tie Y, Hong WQ, He X, Min L, Zhou Y, Luo Y, Chen SY, Yang JY, Shi HH, Wei XW, Tu CQ. Patient-Derived Tumor Xenografts Plus Ex Vivo Models Enable Drug Validation for Tenosynovial Giant Cell Tumors. Ann Surg Oncol 2021. [PMID: 33748895 DOI: 10.1245/s10434-021-09836-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Spierenburg G, van der Heijden L, van Langevelde K, Szuhai K, Bovée JVGM, van de Sande MAJ, Gelderblom H. Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches. Expert Opin Ther Targets 2022. [PMID: 35443852 DOI: 10.1080/14728222.2022.2067040] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Tang F, Tie Y, Wei YQ, Tu CQ, Wei XW. Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials. Biochim Biophys Acta Rev Cancer 2021;1876:188606. [PMID: 34371128 DOI: 10.1016/j.bbcan.2021.188606] [Reference Citation Analysis]
3 Tang F, Tie Y, Wei X, Tu C. ASO Author Reflections: Patient-Derived Tumor Xenografts and Ex Vivo Models Mimic the Clinical Response of Locally Aggressive Tumors to Approved Drug Candidates. Ann Surg Oncol 2021. [PMID: 33738717 DOI: 10.1245/s10434-021-09840-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]